GlassScriptPhysician profile
Samir Fahed
NPI 1063698645
$3,643.39
in general payments reported to CMS, 2019-2025
27 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $181 · 2021: $803 · 2022: $845 · 2023: $895 · 2024: $380 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,409.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $1,425.22 | 2019-2024 | Senza, Vyrsa V1 |
| Boston Scientific Corporation | $515.00 | 2020-2023 | |
| Vertos Medical, INC. | $250.19 | 2019-2022 | |
| Medtronic, INC. | $210.32 | 2023-2025 | Intellis Adaptivestim, V-Loc 180 |
| Stimwave Technologies Incorporated | $193.33 | 2019-2022 | |
| Epimed International, INC | $126.68 | 2021 | |
| Abbott Laboratories | $114.13 | 2021-2024 | Eterna, Proclaim |
| Curonix LLC | $97.95 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Horizon Therapeutics Plc | $97.92 | 2020-2022 | |
| Painteq LLC | $88.26 | 2022-2023 | Painteq |
| Scilex Pharmaceuticals INC. | $74.32 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.44 | 2023 | Relistor |
| Spr Therapeutics, INC | $48.00 | 2022 | |
| Valinor Pharma, LLC | $38.98 | 2025 | Movantik |
| Fidia Pharma USA INC. | $35.46 | 2023-2025 | Triluron, Hymovis |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $29.83 | 2021 | |
| Abbvie INC. | $29.82 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $29.06 | 2022 | |
| Globus Medical, INC. | $27.86 | 2025 | Senza |
| Foundation Fusion Solutions, LLC | $26.64 | 2021 | |
| Capsovision, INC. | $25.19 | 2024 | Capsocam Plus |
| Amniox Medical, INC. | $20.45 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.69 | 2022 | |
| Almatica Pharma LLC | $15.15 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.61 | 2021 | |
| Collegium Pharmaceutical, INC. | $13.51 | 2021 | |
| Daiichi Sankyo INC. | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Fahed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.